YOD1 and prostate carcinoma: They noted that NONHSAT-210528 promoted the expression of YOD1, an element involved in the regulation of enzalutamide resistance, by participating in the regulation of miR-21-5p expression in enzalutamide-resistant prostate cancer cells and that when the miR-21-5p expression was inhibited, the invasive effect of LncRNA-NONHSAT-210528 on enzalutamide-resistant cells was significantly reduced.